Abstract:The von Willebrand factor-cleaving protease (vWF-cp) is a newly identified plasma metalloproteinase and plays an important role in the pathogenesis of thrombotic microangiopathy. In the present study, the metalloproteinase domain of vWF-cp was expressed by IPTG-induced the recombinant engineered E.coli strain harbouring pET28a (+)-vWF-cp/MD and purified using chromatography on Ni-NTA column. Then the BALB/c mice were immunized with the recombinant protein to prepare the monoclonal antibodies (McAb) against vWF-cp and the obtained McAbs were characterized. Furthermore, the expression panels of vWF-cp in human normal tissues were investigated using immunohistochemistry. The results showed that high-level expression of the recombinant protein was achieved, which existed as inclusion body and amounted to 28% of total bacteria protein. Three monoclonal antibodies against the metalloproteinase domain of vWF-cp were obtained and two of them, SZ-112 and SZ-113, were further evaluated. Both of them belong to IgG(1). The concentration of them in ascites was 4 mg/ml, and their titers were as high as 1 x 10(-5). The data of ELISA showed that SZ-112 and SZ-113 recognized different epitopes of recombinant protein. The Western blot and immunoprecipitation data showed that the two monoclonal antibodies reacted not only with the recombinant protein, but also with a 200 kD protein in platelet lysate. Moreover, the vWF-cp was found to be present in the cytoplasm of many human tissues such as liver, prostate, ovary, etc. However, the protease could not be detected in brain tissue. In conclusion, the above-mentioned research work contributed not only to the further study of the structure and function of this protease, but also to the establishment of the method for quantifying the vWF-cp antigen in plasma.

[Identification of Monoclonal Antibodies Against Von Willebrand Factor Cleaving Protease (ADAMTS13) and Their Function].

A Novel Monoclonal Antibody Against A2 Domain of Von Willebrand Factor Reduces Its Proteolysis by ADAMTS13

Correction: A Conformation-Sensitive Monoclonal Antibody Against the A2 Domain of Von Willebrand Factor Reduces Its Proteolysis by ADAMTS13

[Stable Expression and Characterization of the Von Willebrand Factor Cleaving Protease].

The Development of Monoclonal Anti-Adamts18 Antibodies with Precise Validation of ADAMTS18 Post-Translational Modification Status in Living Organisms.

Preparation and Characterization of Monoclonal AntibodyAgainst Human Von Willebrand Factor

A novel monoclonal antibody against the von Willebrand Factor A2 domain reduces its cleavage by ADAMTS13

[Development of Hybridoma Cell Lines Secreting Monoclonal Antibodies Against ADAMTS13].

[Expression of the Metalloproteinase Domain of Von Willebrand Factor-Cleaving Protease and Preparation of Its McAb].

Dynamic and Functional Linkage Between Von Willebrand Factor and ADAMTS-13 with Aging: an Atherosclerosis Risk in Community Study.

Characterization and Functional Studies of Vwf A3 Domain Monoclonal Antibodies That Inhibit Binding of Vwf to Collagen

Purification and Functional Characterization of Two Thrombosis-Related Molecules: Von Willebrand Factor and ADAMTS-13

A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD

[Expression of Vwf73 and VWF114 Fragments of Von Willebrand Factor A2 Domain and Their Utilization in Detecting ADAMTS13 Activity].

[Biological Function of CysR Domain of ADAMTS13].

Epitope Mapping Of A Monoclonal Antibody Against Vwf Which Diminishes The Proteolytic Cleavage Of Vwf By Adamts13 Under Flow

Allosteric Activation of ADAMTS13 by Von Willebrand Factor.

Preparation of A Monoclonal Antibody Against Human Von Willebrand Factor A1 Domain

[Research on the C-terminal Domain of ADAMTS13 Regulates Its Cleaving Activity].

Effect of Recombinant Protein in the Spacer Domain on ADAMTS13 Activity

AFM Imaging Reveals Multiple Conformational States of ADAMTS13.